

RecombiMAb™ Recombinant Antibodies

Murinized Recombinant Monoclonal Antibodies


bioxcell.com




RecombiMAb™ Recombinant Antibodies

RecombiMAb™ Primary Antibodies


RecombiMAb™ antibodies use mouse or human IgG constant regions instead of the typical rat or hamster IgG constant regions, resulting in improved *in vivo* activity and reduced immunogenicity in mouse and humanized mouse models. In some syngeneic mouse tumor models, particularly in BALB/c mice, repeated rat or hamster IgG administration can result in complications from hypersensitivity reactions. Using the RecombiMAb™ antibody instead of wild-type clones may reduce antibody immunogenicity and alleviate hypersensitivity reactions. RecombiMAb™ antibodies also overcome the limitations of traditionally manufactured antibodies by ensuring high lot-to-lot consistency and data reproducibility across experiments.




RecombiMAb™ anti-mouse PD-1 (CD279) (D265A) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the RMP1-14-CP151 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The RMP1-14-CP151 values (purple squares) were normalized to the isotype control antibody values (grey circles).



RecombiMAb™ anti-mouse PD-1 (CD279) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the RMP1-14-CP157 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The RMP1-14-CP157 values (purple squares) were normalized to the isotype control antibody values (grey circles).



RecombiMAb™ anti-mouse PD-1 (CD279) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the 29F.1A12-CP159 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The 29F.1A12-CP159 values (purple squares) were normalized to the isotype control antibody values (grey circles).



RecombiMAb™ anti-mouse PD-L1 (B7-H1) blocks the binding of PD-1 to PD-L1. Mouse PD-L1 was immobilized on a plate and incubated with mouse PD-1 and the 10F.9G2-CP168 antibody. Bound PD-1 was quantified with an HRP conjugate system as absorbance @450 nm. The 10F.9G2-CP168 values (purple squares) were normalized to the isotype control antibody values (grey circles).

Antigen	Reactivity	Host / Isotype	Mutation(s)	Application(s)	Clone	Catalog Number	Isotype Control
4-1BB (CD137)	Mouse	Mo, IgG1		<i>in vivo</i> activation of 4-1BB	LOB12.3-CP035	CP035	BP0083
4-1BB (CD137)	Mouse	Mo, IgG2a		<i>in vivo</i> activation of 4-1BB	LOB12.3-CP037	CP037	BP0085
4-1BB (CD137)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> activation of 4-1BB	LOB12.3-CP036	CP036	
4-1BB (CD137)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> activation of 4-1BB	LOB12.3-CP038	CP038	
4-1BBL (CD137L)	Mouse	Mo, IgG2a		<i>in vivo</i> 4-1BBL blockade, ELISA	TKS-1-CP040	CP040	BP0085
4-1BBL (CD137L)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> 4-1BBL blockade, ELISA	TKS-1-CP039	CP039	
4-1BBL (CD137L)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> 4-1BBL blockade, ELISA	TKS-1-CP041	CP041	
CD4	Mouse	Mo, IgG2b, κ		<i>in vivo</i> CD4+ T cell depletion, FC, WB	GK1.5-CP127	CP127	BP0086
CD8α	Mouse	Mo, IgG2b, κ		<i>in vivo</i> CD8+ T cell depletion, WB	2.43-CP128	CP128	BP0086
CD8α	Mouse	Mo, IgG2a, κ		<i>in vivo</i> CD8+ T cell depletion, WB	YTS 169.4-CP134	CP134	BP0085
CD16/CD32	Mouse	Mo, IgG2a		<i>in vitro</i> Fc receptor blocking, <i>in vivo</i> Fc receptor blocking	2.4G2-CP025	CP025	BP0085
CD16/CD32	Mouse	Mo, IgG2a	LALA-PG	<i>in vitro</i> Fc receptor blocking, <i>in vivo</i> Fc receptor blocking	2.4G2-CP026	CP026	
CD28	Mouse	Mo, IgG2a		<i>in vivo</i> T cell stimulation/activation, <i>in vitro</i> T cell stimulation/activation	D665-CP042	CP042	BP0085
CD28	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> T cell stimulation/activation, <i>in vitro</i> T cell stimulation/activation	D665-CP043	CP043	
CD40	Mouse	Mo, IgG2a, κ		<i>in vivo</i> CD40 activation, <i>in vitro</i> B cell stimulation/activation	FGK4.5-CP133	CP133	BP0085
CD40L (CD154)	Mouse	Mo, IgG2a		<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP033	CP033	BP0085
CD40L (CD154)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP032	CP032	
CD40L (CD154)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP034	CP034	
CD71 (TFR1)	Mouse	Mo, IgG2a, κ		<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3-CP130	CP130	BP0085
CSF1R (CD115)	Mouse	Mo, IgG2a, κ		<i>in vivo</i> macrophage depletion, <i>in vitro</i> CSF1R neutralization, <i>in vivo</i> monocyte depletion, FC, WB	AFS98-CP131	CP131	BP0085
CTLA-4 (CD152)	Mouse	Mo, IgG1, κ		<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP146	CP146	BP0083
CTLA-4 (CD152)	Mouse	Mo, IgG1		<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP006	CP006	BP0083
CTLA-4 (CD152)	Mouse	Mo, IgG2a		<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP007	CP007	BP0085
CTLA-4 (CD152)	Mouse	Mo, IgG2a		<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP011	CP011	BP0085
CTLA-4 (CD152)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP010	CP010	
CTLA-4 (CD152)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP008	CP008	
CTLA-4 (CD152)	Mouse	Mo, IgG2b	LALA-PG	<i>in vivo</i> CTLA-4 neutralization, WB	9D9-CP009	CP009	

Antigen	Reactivity	Host / Isotype	Mutation(s)	Application(s)	Clone	Catalog Number	Isotype Control
CTLA-4 (CD152)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> CTLA-4 neutralization, <i>in vitro</i> CTLA-4 neutralization, WB	9H10-CP012	CP012	
GITR	Mouse	Mo, IgG2a		<i>in vivo</i> GITR stimulation	DTA-1-CP028	CP028	BP0085
GITR	Mouse	Mo, IgG2b		<i>in vivo</i> GITR stimulation	DTA-1-CP030	CP030	BP0085
GITR	Mouse	Mo, IgG2b	LALA-PG	<i>in vivo</i> GITR stimulation	DTA-1-CP031	CP031	
GITR	Mouse	Mo, IgG1	D265A	<i>in vivo</i> GITR stimulation	DTA-1-CP027	CP027	
CD40L (CD154)	Mouse	Mo, IgG2a		<i>in vivo</i> & <i>in vitro</i> blocking of CD40/CD40L signaling, WB	MR-1-CP033	CP033	BP0085
ICOSL (CD275)	Mouse	Mo, IgG2a		<i>in vivo</i> ICOSL neutralization	HK5.3-CP045	CP045	BP0085
ICOSL (CD275)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> ICOSL neutralization	HK5.3-CP044	CP044	
ICOSL (CD275)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> ICOSL neutralization	HK5.3-CP046	CP046	
LAG-3	Mouse	Mo, IgG2a		<i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB	C9B7W-CP014	CP014	BP0085
LAG-3	Mouse	Mo, IgG1	D265A	<i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB	C9B7W-CP013	CP013	
LAG-3	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> LAG-3 neutralization, <i>in vitro</i> LAG-3 neutralization, FC, WB	C9B7W-CP015	CP015	
OX40 (CD134)	Mouse	Mo, IgG2a		<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX86-CP017	CP017	BP0085
OX40 (CD134)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX86-CP016	CP016	
OX40 (CD134)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> OX40 activation, <i>in vitro</i> OX40 activation, WB	OX86-CP018	CP018	
PD-1 (CD279)	Mouse	Mo, IgG2a, κ	D265A	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP151	CP151	CP150
PD-1 (CD279)	Mouse	Mo, IgG2a, κ	L234A, L235A, P329G (LALA-PG)	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP153	CP153	CP150
PD-1 (CD279)	Mouse	Mo, IgG2a, κ		<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP157	CP157	BP0085
PD-1 (CD279)	Mouse	Mo, IgG1, κ		<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, FC, WB	29F.1A12-CP159	CP159	BP0083
PD-1 (CD279)	Mouse	Mo, IgG1, κ		<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP162	CP162	BP0083
PD-1 (CD279)	Mouse	Mo, IgG2c		<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP003	CP003	BE0366
PD-1 (CD279)	Mouse	Mo, IgG1		<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC	29F.1A12-CP004	CP004	BP0083
PD-1 (CD279)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> blocking of PD-1/PD-L signaling	RMP1-14-CP002	CP002	
PD-1 (CD279)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> blocking of PD-1/PD-L signaling, <i>in vitro</i> PD-1 neutralization, IHC-F, IF, WB, FC	29F.1A12-CP005	CP005	
PD-L1 (B7-H1)	Mouse	Mo, IgG1, κ		<i>in vivo</i> PD-L1 blockade, IF, IHC (frozen), FC	10F.9G2-CP168	CP168	BP0083
PD-L1 (B7-H1)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> PD-L1 blockade, IF, IHC (frozen), FC, WB	10F.9G2-CP001	CP001	
PD-L2 (B7-DC)	Mouse	Mo, IgG2a		<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC (frozen), FC	TY25-CP023	CP023	BP0085
PD-L2 (B7-DC)	Mouse	Mo, IgG1	D265A	<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC (frozen), FC	TY25-CP022	CP022	
PD-L2 (B7-DC)	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> PD-L2 blockade, <i>in vitro</i> PD-L2 blockade, IHC (frozen), FC	TY25-CP024	CP024	
VEGFR-2	Mouse	Mo, IgG2a, κ		<i>in vivo</i> blocking of VEGF/VEGFR-2 signaling, <i>in vitro</i> blocking of VEGFR signaling, WB	C101-CP132	CP132	BP0085
VISTA	Mouse	Mo, IgG2a		<i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling	13F3-CP020	CP020	BP0085
VISTA	Mouse	Mo, IgG1	D265A	<i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling	13F3-CP019	CP019	
VISTA	Mouse	Mo, IgG2a	LALA-PG	<i>in vivo</i> blocking of VISTA signaling, <i>in vitro</i> blocking of VISTA signaling	13F3-CP021	CP021	

RecombiMab™ Isotype Control Antibodies

RecombiMab™ isotype control antibodies are recombinantly expressed, ensuring extremely high lot-to-lot consistency and data reproducibility from experiment to experiment. All RecombiMab™ antibodies are screened for murine pathogens using ultrasensitive qPCR, screened for protein aggregation, and are guaranteed to contain less than 1 endotoxin unit per milligram.

Product Name	Host / Isotype	Mutation(s)	Clone	Catalog #
Human IgG1 (LALA-PG) isotype control, anti-respiratory syncytial virus	Human IgG1	L234A, L235A, P329G (LALA-PG)	Palivizumab-CP161	CP161
human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme	Human IgG1	L234A, L235A, P329G (LALA-PG)	N/A-CP149	CP149
Human IgG1 isotype control, anti-respiratory syncytial virus	Human IgG1, κ		Palivizumab-CP169	CP169
Human IgG4 S228P L235E P329G (SPLEPG) isotype control, anti-hen egg lysozyme	Human IgG4	S228P, L235E, P329G	N/A-CP148	CP148
Human IgG4 (S228P) isotype control, anti-hen egg lysozyme (HEL)	Human IgG4, κ	S228P	N/A-CP147	CP147
Human IgG4 (S228P) isotype control, anti-respiratory syncytial virus	Human IgG4, κ	S228P	Palivizumab-CP152	CP152
Mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme	Mouse IgG2a	D265A	N/A-CP150	CP150
Mouse IgG2a isotype control, unknown specificity	Mouse IgG2a		MOPC-21-CP160	CP160

Don't see a recombinant antibody of your interest? Contact us for more information on recombinant antibody production and transient expression services at: contractservices@bioxcell.com

TO LEARN MORE
scan or visit us at
bioxcell.com/recombimab





For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 19,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cell

bioxcell.com

Customerservice@bioxcell.com | 1.866.787.3444

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

